Alfons A den Broeder
Overview
Explore the profile of Alfons A den Broeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
3020
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bolhuis T, Marsman D, den Broeder A, den Broeder N, van der Maas A
Lancet Rheumatol
. 2024 Jan;
5(4):e208-e214.
PMID: 38251523
Background: Rituximab was effective for patients with polymyalgia rheumatica in the 21-week BRIDGE-PMR randomised controlled trial. Here, we aimed to assess rates of glucocorticoid-free remission up to 1 year after...
12.
Verhoef L, den Broeder N, Thurlings R, Van der Laan W, van der Weele W, Kok M, et al.
Lancet Rheumatol
. 2024 Jan;
1(3):e145-e153.
PMID: 38229391
Background: Rituximab is an effective treatment for rheumatoid arthritis, given as either two doses of 1000 mg (2 weeks apart) every 6 months (the dose recommended by the US Food...
13.
Teuwen M, van Weely S, Vliet Vlieland T, van Wissen M, Peter W, den Broeder A, et al.
Ann Rheum Dis
. 2024 Jan;
83(4):437-445.
PMID: 38171602
Objectives: To compare the effectiveness of longstanding (>52 weeks), supervised exercise therapy with usual care in adults with rheumatoid arthritis (RA) and severe functional limitations. Methods: Participants were randomised 1:1...
14.
Teuwen M, van Weely S, Vliet Vlieland T, Douw T, van Schaardenburg D, den Broeder A, et al.
Rheumatol Int
. 2023 Nov;
44(1):129-143.
PMID: 38006457
The objective of the study is to describe the nature of functional limitations in activities and participation in people with Rheumatoid Arthritis (RA) or axial SpondyloArthritis (axSpA) with severe functional...
15.
Popa C, Opdam M, den Broeder N, van Ballegooijen H, Mulder K, van de Wiel K, et al.
Rheumatology (Oxford)
. 2023 Oct;
63(8):2142-2146.
PMID: 37796830
Objective: Caution has been advocated recently when using Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) patients with an unfavourable cardiovascular risk profile. We aimed to compare the incidences in...
16.
den Broeder N, den Broeder A, Verhoef L, van den Hoogen F, van der Maas A, van den Bemt B
Clin Pharmacol Ther
. 2023 Jul;
114(4):810-814.
PMID: 37429827
Tocilizumab and sarilumab are IL-6-receptor antagonists registered for rheumatoid arthritis (RA), with equal effectiveness and safety. Switching from tocilizumab to sarilumab could be a strategy to reduce injection burden, in...
17.
Veeken L, Opdam M, Verhoef L, Popa C, van Crevel R, den Broeder A
Rheumatology (Oxford)
. 2023 Jul;
63(5):1246-1250.
PMID: 37410085
Objectives: Rituximab (RTX) is a safe and effective treatment for RA. However, there are some concerns about infection risk and preliminary data suggest dose and time dependency. This study aims...
18.
Opdam M, Campisi L, de Leijer J, Ten Cate D, den Broeder A
Rheumatology (Oxford)
. 2023 Jul;
63(1):e1-e2.
PMID: 37410082
No abstract available.
19.
Messelink M, den Broeder A, Marinelli F, Michgels E, Verschueren P, Aletaha D, et al.
RMD Open
. 2023 Apr;
9(2).
PMID: 37116986
Objectives: A treat-to-target (T2T) strategy has been shown to be superior to usual care in rheumatoid arthritis (RA), but the optimal target remains unknown. Targets are based on a disease...
20.
Peeters I, den Broeder A, Taylor W, den Broeder N, Flendrie M, van Herwaarden N
Trials
. 2023 Apr;
24(1):282.
PMID: 37072799
Background: Long-term gout treatment is based on reducing serum urate levels using urate-lowering therapy (ULT). Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed...